Migraine drugs developer Slate Medicines is going public in a reverse merger with Fulcrum Therapeutics. The biotech’s lead antibody drug blocks two novel migraine targets, offering the potential for better efficacy compared to other next-generation migraine drugs in R&D.
The post Slate Medicines’ Merger and $245M Private Placement Fuel Mission in Migraine appeared first on MedCity News.
